With Synosia Therapeutics Holding AG being acquired by Biotie Therapies Corp for $129.4 million in an all-stock deal, the pharmaceutical sector in Switzerland witnesses a significant corporate acquisition. The closure of this deal marks a notable shift that could potentially impact the market sentiments and investors' outlook.